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Abstract  
Introduction: Adult-onset Still´s disease (AOSD) is a systemic inflammatory condition 
that affects mainly young people. The clinical course consists of two distinctive 
patterns: one with a predominance of systemic symptoms and another manifested by 
progressive chronic polyarthritis. Glucocorticoids remain the mainstay in the treatment 
of AOSD. However, biologic therapies are often required to achieve clinical remission 
and allow glucocorticoid discontinuation.   
Areas covered: The review summarizes the main retrospective and prospective studies, 
and case series on the use of the anti-interleukin (IL)-6 receptor tocilizumab in AOSD.   
Expert opinion: Since IL-6 serum levels are highly increased in both active systemic 
and polyarticular phenotypes, IL-6 blockade was considered to be a plausible 
therapeutic option for the management of AOSD. Tocilizumab, the only anti-IL-6-
receptor antagonist currently available for AOSD, has proved to be effective for the 
management of refractory AOSD patients, including those with life-threatening 
complications. Nevertheless, there are some reports describing patients who are 
refractory to any therapy. Future research should focus on the identification of 
prognostic biomarkers that help us to tailor an individualized treatment for each type of 
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patient and in the search of new disease activity indices that help us to monitor the 
response to the therapy more closely. 
 
Keywords: adult-onset Still disease, anakinra, anti-IL6-receptor tocilizumab, anti-TNF-
α drugs, biologics, glucocorticoids.  
1. Introduction  
Adult-onset Still´s disease (AOSD) is a systemic inflammatory disease of unknown 
origin affecting mainly young people with an estimated annual incidence between 0.16 
and 0.4/100,000 persons worldwide [1-3]. It is slightly more common in women [4,5], 
and there is a bimodal age distribution, with a peak between 15 and 25 years and 
another around 35-40 years [1].  
AOSD is included within the clinical spectrum of autoinflammatory disorders [6,7]. It 
shares many clinical and laboratory features as well as a gene profile activation with 
systemic onset juvenile idiopathic arthritis (sJIA) [8-10]. Because of that, AOSD and 
sJIA are currently considered two variants of the same disease [3]. In addition, 
extrapolation of the use of biologic therapies in AOSD was partially inferred from the 
good results obtained in sJIA. 
Infectious and other environmental factors may trigger a systemic autoinflammatory 
response in genetically predisposed individuals leading to a dysregulation of the 
“inflammasome complex” with the overproduction of numerous pro-inflammatory 
cytokines such as interleukin (IL)-1, IL-6, IL-18, interferon (IFN)-γ and tumor necrosis 
factor (TNF)-α [10,11].  
AOSD is clinically characterized by daily high spiking fever, evanescent salmon-
colored maculopapular rash, arthritis, musculoskeletal symptoms and neutrophilic 
leukocytosis. Other common manifestations include: sore throat, lymphadenopathy, 
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pulmonary infiltrates, pleuritis, pericarditis, abdominal pain and hepatosplenomegaly 
[3,12,13]. As the result of a systemic inflammatory response, patients with AOSD 
present elevation of acute-phase reactants (APR), such as the erythrocyte sedimentation 
rate (ESR) and the C-reactive protein (CRP), marked leukocytosis with neutrophilia, 
anemia and thrombocytosis. Serum ferritin levels are particularly increased (classically 
more than 5 times above the upper limit of normal) and it may be a good biomarker of 
disease activity [3,13]. AOSD is also associated with a reduction in the glycosylated 
ferritin fraction, so that the combination of serum ferritin levels higher than 1000 µg/L 
with a glycosylated fraction <20% has been found to have a high specificity for a 
diagnosis of the disease [14,15]. 
The presentation and course of AOSD may result into two well differentiated clinical 
phenotypes: a systemic and highly symptomatic pattern (systemic pattern, SP) and 
another consisting of a chronic articular disease (CAD), showing features of persistent 
polyarthritis with progressive joint destruction, and eventually more disabling than the 
SP [10,16]. Sometimes, we are not able to categorize chronic AOSD into two dominant 
forms, because there are mixed forms of the disease. Indeed, systemic form of disease 
may transit to arthritis dominant form and vice versa, which manifests once again the 
heterogeneity of this multifaceted disease. Interestingly, arthritis of the CAD can be 
erosive in up to 50% of patients [17,18]. Around 15-20% of patients with AOSD 
develop some life-threatening complications such as the macrophage activation 
syndrome (MAS), disseminated intravascular coagulation (DIC), severe myocarditis, 
endocarditis or pulmonary arterial hypertension (PAH) [19,20]. In particular, MAS is 
the most severe complication of AOSD, and it is associated with a high mortality rate 
occurring early during the course of the disease [21,22]. IL-6 has been proposed as one 
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of the most important mediators implicated in the pathogenesis of that complication 
[23].  
Due to the low incidence of the disease, the treatment of AOSD remains largely 
empirical, mainly based on case reports and small retrospective case series, and not on 
controlled studies. Non-steroidal anti-inflammatory drugs (NSAIDs) and 
glucocorticoids (GC) represent the first line therapy, particularly for musculoskeletal 
manifestations and fever, with response rates between 20% and 60% [3,12,24]. 
However, around 40-45% of patients with AOSD develop glucocorticoid-dependence 
and/or mild or severe long-term toxicity [25]. Therefore, disease-modifying anti-
rheumatic drugs (DMARDs) such as methotrexate (MTX), cyclosporin A (CsA), 
azathioprine (AZA) or leflunomide (LEF) are often required as second line therapy [24-
26]. In cases refractory to GC and DMARDs, biologic drugs, particularly anti-
interleukin (IL)-1 and anti-IL-6 receptor (R) agents, have proved to be effective to 
control disease activity and its main complications [27-29]. In patients who are 
refractory to these therapies or in those with life-threatening complications other 
therapies such as: intravenous (IV) immunoglobulins, calcineurin inhibitors, 
cyclophosphamide or plasma exchanges may be used [3,12,19].  
Tocilizumab (TCZ), a humanized anti-IL-6R antibody that binds to both the membrane-
bound and soluble form of IL-6R, is an effective biologic agent for the treatment of 
AOSD. Data from retrospective studies and case series demonstrate the efficacy of TCZ 
in monotherapy or combined to DMARDs for refractory AOSD, both in patients with 
the CAD and the SP patterns and for some life-threatening complications of the disease 
[30-33]. In the present review, we have focused on the use of TCZ for the treatment of 
AOSD. Data on the efficacy and safety of TCZ for AOSD therapy are discussed.  
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2. Areas covered 
Glucocorticoids are the cornerstone of treatment of AOSD. However, they are effective 
in only 60% of patients with AOSD [3,13]. They have been reported to be more 
effective in patients with SP than in those with CAD [24]. Conventional 
immunosuppressive agents, mainly MTX, have been used as GC-sparing agents to 
reduce the frequency of relapses. However, results in terms of efficacy have not been 
well established. Large observational studies showed that 17-32% of AOSD patients are 
refractory to GC and conventional DMARDs and require biologic DMARDs therapy 
[34-37]. Among them, anti-IL1 and anti-IL6 agents are those that have shown better 
results.  
Anti-IL1 agents, especially anakinra (ANK) and canakinumab, are especially useful in 
the SP of the disease. ANK has recently been approved by the European Medical 
Agency (EMA) for their use in AOSD [38]. Although the anti-IL-6R TCZ has not 
approved for the use of in AOSD therapy yet, it is commonly use in AOSD as off-label 
treatment. In this regard, the daily clinical practice supports the use of TCZ in patients 
with AOSD. Tumor necrosis factor (TNF) blocking drugs are currently considered as a 
second line of biologic therapy in patients with the CAD pattern [3,28,38]. 
 
3. Unmet needs of currently available therapies in AOSD management 
The diagnosis of AOSD is usually made by the exclusion of other systemic diseases. 
Most clinicians use the criteria proposed by Yamaguchi et al. [39] and Fautrel et al. [40] 
(Table 1). However, there are limitations to determine disease activity, clinical course 
and prognosis. Biomarkers such as ferritin and its glycosylated fraction, procalcitonin, 
serum amyloid A or calprotectin have been used to monitor the disease. However, 
further investigation is needed to establish their applicability in the daily clinical 
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practice [29]. Although the use of biologic agents have been effective to induce 
remission in patients with disease refractory to conventional therapies, no biologic 
therapy is effective in all the patients. Early treatment in essential to modify the clinical 
course of the disease, preventing chronicity and severe complications [3,32,41].  
At present we cannot identify what patients will be refractory to conventional therapies 
and require a biologic agent. In this regard, a third of the patients only have a transient 
monocyclic pattern. On the other hand, there are new biologic agents that it is possible 
that may be more effective than those currently used for the management of refractory 
AOSD. It is the case of sarilumab, a new anti-IL-6 agent that blocks the receptor more 
efficiently than TCZ. Also, other biologic agents, such as the IL-18 and INF-ϒ 
antagonists, may replace the anti-IL-1 and anti-IL-6R antagonists in the near future [29]. 
 
4. Tocilizumab in the treatment of AOSD 
4.1 Introduction to the compound 
IL-6 is a pleiotropic pro-inflammatory cytokine produced by a number of cells 
including T- and B-cells, monocytes and fibroblasts. IL-6 is involved in different 
physiological processes such as T-cell activation, induction of immunoglobulin 
secretion, induction of hepatic acute phase protein synthesis and stimulation of 
hemopoiesis. This cytokine has been implicated in the pathogenesis of a broad spectrum 
of diseases including inflammatory diseases, osteoporosis and neoplasia. IL-6 is also a 
pivotal cytokine involved in the pathogenesis of AOSD, reason why it was considered 
as an important target for the treatment of this disease. Moreover, IL-6 serum levels are 
markedly increased in both the active SP as well as in the active CAD phenotype 
[16,42]. Therefore, IL-6 blockade can be considered to successfully manage, in most 
cases, both arthritis and systemic disease manifestations. 
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Inhibition of IL-6 signaling is possible by several different approaches: direct 
neutralization of the cytokine or blockade of the corresponding receptor, as well as by 
cytoplasmic signaling blockade through Janus kinase (JAK) inhibitors. There are two 
different IL-6R antagonists (TCZ and sarilumab) currently available for treating 
rheumatic diseases. However, only case series using TCZ for AOSD have been reported 
[30,41,43].  
TCZ is a humanized anti-IL-6R antibody that binds to both soluble and membrane-
bound IL-6 receptors (sIL-6R and mIL-6R), inhibiting sIL-6R and mIL-6R-mediated 
signaling. TCZ is available for intravenous (IV) infusion and subcutaneous (SC) 
injections. Due to the extensive experience with TCZ in rheumatoid arthritis (RA), 
many of the pharmacological data that we will present in the following paragraphs are 
based on studies in patients with RA. 
4.2 Clinical indications  
The excellent data in terms of clinical efficacy and safety of TCZ in the treatment of RA 
and other rheumatic diseases supported the use of TCZ in AOSD patients who were 
refractory to GC, conventional DMARDs, and other biologic agents including anti-
TNF-α agents and IL-1 blocking agents [44]. Its use was also supported by results from 
randomized placebo-controlled trials that showed the efficacy of TCZ in children with 
sJIA [45,46].  
TCZ alone or in combination with MTX is indicated for the treatment of severe, active 
and progressive RA in adults not previously treated with MTX or in patients intolerant 
or not responders to previous therapy with one or more conventional DMARDs or TNF-
α antagonists. TCZ is also indicated for the treatment of active sJIA and juvenile 
idiopathic polyarthritis (pJIA) in patients 2 years of age and older, who have responded 
inadequately to previous therapy with NSAIDs and systemic GC [47]. Finally, 
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subcutaneous TCZ is recently approved for the treatment of giant cell arteritis (GCA) 
and intravenous TCZ for the treatment of chimeric antigen receptor (CAR) T cell-
induced severe or life-threatening cytokine release syndrome (CRS) in adults and 
pediatric patients 2 years of age and older [47]. Nevertheless, the use of TCZ in AOSD 
is out of the technical brochure due to the absence of randomized clinical trials 
supporting its use for this specific indication. The posology of TCZ in the different 
clinical scenarios ranges between 4 mg/kg and 8 mg/kg body weight every 2-4 weeks 
for the IV administration and 162 mg weekly or every other week (eow) for the SC 
administration [47]. Table 2 shows the main approved and off-label indications for the 
use of TCZ nowadays. 
4.3 Pharmacodynamics 
TCZ interferes not only with the pathological effects of IL-6, but also with its 
physiological effects at multiple levels. Rapid decreases in CRP, ESR and serum 
amyloid A (SAA) were observed in RA patients undergoing TCZ therapy. Decreases in 
the levels of CRP to within normal ranges are seen as early as week 2, with decreases 
maintained during the treatment [47].  
Consistent with the effect on ARP, TCZ administration was associated with reduction in 
platelet count within the normal range. TCZ also decreases the IL-6 driven effect on 
hepcidin production, leading to an increase of hemoglobin levels due to improvement of 
iron availability.  
The absolute neutrophil count decreased to their lowest levels 3 to 5 days after starting 
the administration in healthy subjects who received TCZ at doses between 2 and 28 
mg/kg. Thereafter, neutrophils recovered towards baseline in a dose dependent manner. 
RA patients showed a similar pattern of absolute neutrophil counts following TCZ 
administration [47].  
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4.4 Pharmacokinetics and metabolism 
The pharmacokinetics (PK) of TCZ was determined using a population PK analysis on a 
database composed of 3552 RA patients treated with a one-hour IV infusion of 4 or 8 
mg/kg TCZ every 4 weeks for 24 weeks or with 162 mg TCZ given subcutaneously 
either once a week or eow for 24 weeks [47]. The dose-response curve for TCZ flattens 
at higher exposures, resulting in smaller efficacy gains for each incremental increase in 
TCZ concentration. Clinically meaningful increases in efficacy were not demonstrated 
in adult patients treated with >800 mg of TCZ. Therefore, TCZ doses exceeding 800 mg 
per infusion are not recommended [47].  
TCZ undergoes a biphasic removal from the circulation after its IV administration. The 
total clearance of TCZ was concentration-dependent and is the sum of the linear and 
non-linear clearances. The t1/2 of TCZ was concentration-dependent. At steady-state 
following a dose of 8 mg/kg every 4 weeks, the effective t1/2 decreased with decreasing 
concentrations within a dosing interval from 18 days to 6 days.  
There are no formal studies on the effect of renal or liver impairment on the PK of TCZ. 
Most patients in the population PK analysis had normal renal function or mild renal 
impairment. Mild renal impairment (creatinine clearance <80 mL/min and ≥50 mL/min) 
did not influence the PK of TCZ. Finally, population PK analyses in RA patients 
showed that age, gender and ethnic origin did not affect the PK of TCZ [47]. 
PK analyses in patients with RA did not show any effect of MTX, NSAIDs or GC on 
TCZ clearance. Concomitant administration of a single IV dose of 10 mg/kg TCZ with 
10-25 mg MTX once weekly had no clinically significant effect on MTX exposure.  
In vitro studies showed that TCZ has the potential to affect expression of multiple CYP 
enzymes including cytochrome P450 (CYP)1A2, CYP2B6, CYP2C9, CYP2C19, 
CYP2D6 and CYP3A4 [47,48].  
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In vivo studies with omeprazole, metabolized by CYP2C19 and CYP3A4, and 
simvastatin, metabolized by CYP3A4, showed up to a 28% and 57% decrease in 
exposure one week following a single dose of TCZ, respectively [47-49]. The effect of 
TCZ on CYP enzymes may be clinically relevant for CYP450 substrates with narrow 
therapeutic index (e.g., warfarin, cyclosporine or theophylline). Special attention should 
be paid when TCZ is coadministered along with CYP3A4 substrate drugs in which a 
reduction in their effectiveness is undesirable, e.g., oral contraceptives, lovastatin, 
atorvastatin, etc. The effect of TCZ on CYP450 enzyme activity may persist for several 
weeks after discontinuation of the therapy [47-49]. 
4.5 Clinical efficacy of IL-6 pathway inhibition 
Overall, the anti-inflammatory efficacy of TCZ in AOSD is good, rapid and sustained 
for most patients. Systemic manifestations improve more rapidly than joint 
manifestations [50].  
Data on the efficacy of TCZ in AOSD are based on several small prospective studies, 
retrospective studies and case series performed mainly in patients with AOSD refractory 
to GC, anti-TNF-α drugs and anti-IL-1 agents [30,31,41,43,50-53]. A recent meta-
analysis of 10 original studies (147 subjects) on the efficacy of TCZ in AOSD showed 
overall high partial and complete remission rates of 85% and 77%, respectively. TCZ 
prevented new flares, it was well tolerated and allowed substantially to reduce the need 
for GC [31,33]. Recently, it has been published the first double-blind, randomized, 
placebo-controlled phase III clinical study with TCZ vs. placebo in 27 patients with 
AOSD refractory to glucocorticoids and systemic manifestations, with promising results 
[54]. 
4.5.1 Prospective studies 
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In a small cohort study, Puéchal et al. assessed the efficacy and safety of TCZ in 14 
patients with refractory AOSD [30]. Prior to the introduction of TCZ, all patients had 
joint symptoms (mean baseline DAS28: 5.61), and half of the patients also had systemic 
manifestations. All patients received 5-8 mg/kg of intravenous TCZ every 2-4 weeks (8 
mg/kg/month IV in 9 cases) during 6-months. Overall, 64% (9/14) of patients 
experienced a good EULAR arthritis response at 3 months, and 57% (8/14) had a mean 
DAS28 of 2.92 at 6 months. Systemic symptoms resolved in 86% of patients, and GC 
dose was decreased from 23.3 to 10.3 mg/day. Three patients withdrew from the study 
due to necrotizing angiodermatitis, chest pain/chills during infusion, and systemic flare, 
respectively [30] (Table 3). 
Kim et al. reported 8 patients with AOSD treated with TCZ (8 mg/kg IV every 4 weeks) 
who had been refractory to DMARDs and/or etanercept [55]. Four patients achieved 
complete and 3 partial response after an average of 6.3 doses (range 2-13 doses), 
Improvement of clinical symptoms was observed after a mean of 4 weeks. The ESR, 
CRP, serum ferritin, IL-18, and IL-6 levels improved within 6.3 weeks, 6.3 weeks, 9.3 
weeks, 12.5 weeks, and 9.3 weeks, respectively. Three patients discontinued the study, 
one each due to severe headache and chest discomfort, neutropenia, and hepatotoxicity. 
Other adverse events (AEs) including mild dizziness, hair loss, weight gain, and 
transient leukopenia were also reported [55]. 
Kondo et al. conducted a prospective, single-arm study to assess the efficacy and safety 
of single-agent TCZ as induction therapy for AOSD [56]. Eight patients (2 men and 6 
women) received TCZ 8 mg/kg every 2 weeks for 5 doses and then monthly for 5 
months. At month 6, white blood cell (WBC) count declined from 14.075 ± 4.732/mm3 
to 7.042 ± 2.939/mm3 (p<0.01), CRP decreased from 12.2 ± 7.4 mg/dL to 0.32 ± 0.62 
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mg/dL (p<0.01), and ferritin dropped from 9.176 ± 8.077 ng/mL to 3.380 ± 5.616 
ng/mL (p<0.01). Fever, arthralgia, and rash improved in eight, six, and five patients, 
respectively. Two patients required prednisolone therapy. Three patients stopped 
treatment due to lack of efficacy (n=2) and an AE (n=1) [56].  
Li et al. described the efficacy and safety of TCZ in 8 women with refractory AOSD. 
They defined refractory disease in case of no response/dependence on GC, no 
response/intolerance to immunosuppressants or acute phase disease complicated by 
hepatic dysfunction or MAS [57]. TCZ was dosed at 4-8 mg/kg every 4 weeks. At 3 
months, fever and rashes remitted in 7 of 8 patients and arthritis in all of them. WBC 
count, ESR, CRP, and ferritin levels significantly decreased (p<0.01) and the average 
prednisone dose was lowered from 51.3 ± 31.9 to 12.9 ± 7 mg/day (p<0.01) [57].  
Muraviev et al. conducted a small study including 6 women and 1 man with AOSD 
(average age 34.2 ± 10.7 years) refractory to NSAIDs, prednisolone, and MTX [58]. All 
patients had fever, typical rash, arthritis, leukocytosis (>10 x 109/L; n=5), throat pain 
(n=4), hepatic disturbances and lymphadenopathy, and received TCZ 8 mg/kg IV every 
4 weeks. After the first dose of TCZ, fever resolved in 6 patients within 24 hours and in 
1 patient within 48 hours. Arthritis symptoms resolved in 2 patients and were 
significantly improved in 5; CRP levels decreased in all patients. Six patients were 
maintained on TCZ, 1 patient achieved remission, and 5 showed improvement [58]. 
Summary of main prospective and retrospective studies published up to date are shown 
in table 3.  
4.5.2 Retrospective Studies 
Ortiz-Sanjuan et al. conducted a retrospective, open-label study that included 34 
Spanish patients with AOSD who underwent TCZ. Twenty-two received 8 mg/kg IV 
every 4 weeks, 10 were treated with 8 mg/kg IV every 2 weeks and 2 with 4 mg/kg IV 
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every 4 weeks, with maintenance doses ranging from 4-8 mg/kg IV every 2 or 4 weeks 
[50]. All patients had experienced an inadequate response to GC and at least to one 
synthetic DMARD, and 50% had also failed a previous biologic agent. After 1 year of 
therapy, improvement from baseline was observed in joint manifestations (97.1% at 
baseline to 32.4%), cutaneous manifestations (58.8% to 5.9%), fever (58.8% to 5.9%), 
lymphadenopathy (29.4% to 0%), splenomegaly/hepatomegaly (11.8% to 0%), and 
pleuritis/pericarditis (8.8% to 0%). The following laboratory parameters also showed 
reduction at month 12 when compared with baseline results: abnormal CRP (82.4% at 
baseline to 23.5%) at month 12, elevated ESR (from 79.4% to 2.9%), leukocytosis 
(from 55.9% to 17.6%), anemia (from 44.1% to 2.9%), and elevated serum ferritin 
levels (from 47.1% to 2.9%). Additionally, the median dose [IQR] of prednisone 
decreased from 13.8 [5-45] mg/day at baseline to 2.5 [0-30] mg/day at 12 months. 
Infections were the most common AEs (n=10) after a median follow-up of 19 months, 
that led to discontinuation of therapy in 2 patients. Other AEs included leukopenia or 
neutropenia (n=4), hepatic enzyme elevations (n=4), hypercholesterolemia (n=1), and 
headache associated with TCZ infusion (n=1) [50] (Table 3).  
Song et al. performed a multicenter, retrospective study evaluating the efficacy of TCZ 
in 24 patients with AOSD [51]. The mean disease duration was 48.4 ± 43.7 months 
before TCZ onset with 12 patients exhibiting CAD, 11 patients with polycyclic SP, and 
1 patient unclassified. Before TCZ therapy most patients had been treated with MTX 
(n=17) and various other conventional and biologic DMARDs. Eleven patients were 
evaluated at 12 months. Patients received a mean TCZ dose of 6.9 mg/kg (4-8 mg/kg) 
every 4 weeks for 8.4 ± 6.8 months. Response to TCZ was measured as a decrease in 
modified Pouchot’s score ≥2 points from baseline for 2 consecutive months. The 
endpoint was not found to be statistically significant as the modified Pouchot’s had a 
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mean decrease from 3.0 ± 1.9 at baseline to 1.1 ± 0.7 at 12 months. The mean CRP and 
ESR were significantly lower at 12 months when compared to baseline. The mean 
prednisolone dose decreased from 15.4 mg/day at baseline to 7.8 mg/day at 12 months. 
AEs occurred in 25% of patients including infusion reactions (n=2), gastrointestinal 
issues (n=2), leukopenia (n=1), and tuberculosis (n=1). Four patients relapsed after TCZ 
was discontinued for 5.0 ± 3.6 months [51] (Table 3).  
Suematsu et al. described the therapeutic response in 16 patients with AOSD who were 
treated with at least 1 biological agent [52]. All patients were refractory to high-dose 
GC and/or at least 1 immunosuppressant. The study included 4 men and 12 women with 
a mean duration of disease of 8.9 years (range 0.2-16.8 years). Eleven patients received 
TCZ 8 mg/kg/month IV. Six of these them received TCZ as the first biologic agent 
whereas 5 patients were switched from another biologic. TCZ achieved remission in 10 
of the 11 patients. Ferritin and CRP levels approached normalization within a mean of 
5.8 and 7.1 weeks, respectively. Resolution of fever and arthralgia occurred within 3.6 
weeks and 5 weeks, respectively. After a median treatment duration of 11.6 months, 
patients who received TCZ had a mean reduction in glucocorticoid dose of 16.8 ± 17.2 
mg. AEs included urinary tract infection, liver dysfunction, and stomatitis [52]. 
Elkayam et al. described 15 patients with AOSD who were treated with TCZ 8 mg/kg 
IV every month (n=12) or 8 mg/kg IV twice a month (n=3) [43]. Ten patients 
previously failed to at least one anti-TNF agent and all patients had arthralgia/arthritis at 
baseline. After 6 months, swollen and tender joint counts decreased from 8.6 ± 5.4 and 
11.6 ± 6.8 to 1.09 ± 1.6 and 2 ± 1.8, respectively (p<0.05 for both). CRP and ESR levels 
decreased from 11.6 ± 15 mg/dL and 60 ± 28 mm/h at baseline to 0.5 ± 0.1 mg/dL and 
3.9 ± 1.4 mm/h, respectively (p<0.05 for both comparisons). The mean prednisone dose 
decreased from 27.6 ± 26.3 mg/day at baseline to 4.9 ± 4 mg/day. By the end of the 
Ac
ce
pte
d M
an
us
cri
pt
mean 15.7 month follow-up, 9 patients had discontinued prednisone, none reported 
systemic symptoms, and 2 only had mild arthralgia. One patient who developed MAS 
after 11 months of treatment responded to an increased dose of prednisone and was 
switched to another biologic agent [43]. 
Kim et al. retrospectively evaluated 37 patients with AOSD refractory to conventional 
therapy who were treated with biologic agents including TCZ IV (n=13) at doses similar 
to those used for RA [59]. Significantly more patients responded to TCZ (84.6%) than 
anti-TNF agents (45.9%) or ANK (50%; p<0.05). All but one of the 6 patients who 
were switched from an anti-TNF agent to TCZ responded. AEs were reported in 46.2% 
of TCZ-treated patients [59]. 
Cipriani et al. described 11 patients (age range, 28-73 years) with AOSD refractory to 
conventional therapy who were treated with TCZ 8 mg/kg IV every 4 weeks for 12 
months and followed up for another additional 6 months [41]. The median DAS28 
decreased from 5.62 at baseline to 2.31 at 3 months, 1.88 at 6 months and 1.61 at 12 
months. Nine patients (81.82%) achieved DAS28<2.6 at 12 months. All patients 
experienced a remission of fever (8 patients presented with fever at baseline) and an 
improvement in systemic symptoms. Tender joint and swollen joint count decreased 
significantly after 6 and 12 months of therapy (p<0.05). At 12 months, the median 
prednisone dose decreased from 50 (25-100) mg/day at baseline to 0 (0-12.5) mg/day 
and 8 of 11 patients were able to discontinue prednisone. At 18 months, 8 patients 
(72.72%) maintained clinical remission while on MTX only. No serious AEs or deaths 
were reported [41].  
Additional studies with ≤ 10 cases per study are shown in table 4 [60,61].  
4.5.3 Case series 
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The first experimental and successful trial of TCZ for a refractory case of AOSD was 
reported by Iwamoto el at in 2002 [62]. Since then, multiple case series describing the 
use of TCZ for the treatment of AOSD have been published [63-71]. Many of the 
patients had refractory disease following treatment with standard therapies such as GC, 
MTX, conventional DMARDs, and anti-TNF agents. The patients´ age ranged from 17 
to 73 years old. Efficacy and safety outcomes varied, but generally, clinical and 
laboratory markers improved significantly following therapy with TCZ. Some of the 
safety outcomes reported included rash, psoriasis, MAS, systemic flares, and 1 death 
from a respiratory infection [63-71].  
A recent systematic review of case reports or case series showed that 35 patients 
received TCZ for the treatment of AOSD (8 mg/kg/ month in 22 patients) until 2013 
[69]. The main clinical manifestations were arthritis in all patients and systemic 
symptoms such as fever or skin rash in 28 (80%). Thirty-three (94%) patients had been 
treated with other immune modulators such as MTX, TNF-α blockers or ANK without 
efficacy. Most patients achieved clinical response to TCZ; prompt joint improvement in 
30/35 (86%) patients and a resolution of systemic features in 27/28 (96%). Twenty-
eight (80%) patients were able to reduce glucocorticoid dosage, and 7 patients 
discontinued glucocorticoid therapy [69]. 
Finally, some case reports have indicated that the IL-6 blockade is effective for the 
treatment of AOSD-related systemic complications including PAH, or MAS induced by 
other treatments [72-74]. 
4.5.4 Clinical trials 
The only randomized, double-blind, placebo-controlled study with TCZ vs. placebo in 
AOSD available up to date has recently been conducted by Kaneko et al in 27 patients 
with AOSD with systemic manifestations who were refractory to glucocorticoids [54]. 
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In this study, patients were randomized to TCZ (8 mg/kg) intravenously administered or 
placebo every 2 weeks during 12-weeks. Later, all patients received TCZ for 40 weeks 
in an open-label continuation study. The primary outcome was the American College of 
Rheumatology (ACR) 50 response at week 4. The secondary outcomes included ACR 
20/50/70, systemic feature score, glucocorticoid dose and adverse events at each point 
[54]. 
In the full analysis set, ACR50 response at week 4 was achieved in 61.5% of patients 
from the TCZ group and 30.8% of the patients from the placebo group (p=0.24). The 
change in systemic feature score at week 12 was -4.1 in the TCZ group and -2.3 in the 
placebo group (p=0.003). The dose of glucocorticoids at week 12 decreased by 46.2% 
in the TCZ group and 21.0% in the placebo group (p=0.017). At week 52, the rates of 
ACR20, ACR50 and ACR70 were 84.6%, 84.6% and 61.5%, respectively. Serious 
adverse events in all participants who received at least one dose of TCZ were infections, 
aseptic necrosis in the hips, exacerbation of the disease, drug eruption and anaphylactic 
shock. The study suggests that TCZ is effective in AOSD, although solid conclusions 
were not drawn due to the small sample size [54]. 
4.5.5 Safety profile and tolerability  
The most commonly reported AEs (occurring in ≥5% of patients treated with TCZ in 
monotherapy or in combination with DMARDs) were upper respiratory tract infections, 
nasopharyngitis, headache, hypertension, neutropenia and increased hepatic alanine 
aminotransferase (ALT). The most serious AEs were serious infections, complications 
of diverticulitis, and hypersensitivity reactions. Once again, the most extensive 
information on AEs comes from that observed in patients with RA, where much more 
experience is available. Table 5 shows the main AEs detected in people with RA treated 
with TCZ in clinical trials. 
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Special mention requires the occurrence of lipid alterations in these patients. Elevations 
in lipid parameters including total cholesterol (TC), low-density lipoprotein (LDL), 
high-density lipoprotein (HDL) and triglycerides were observed in clinical trials in 
patients treated with TCZ. During the 6-month controlled trials performed in RA 
patients treated with TCZ, 24% of patients receiving TCZ experienced sustained 
elevations in TC ≥ 6.2 mmol/L, with 15% experiencing a sustained increase in LDL to ≥ 
4.1 mmol/L. However, in the majority of patients, there was no increase in the 
atherogenic indices, and elevations in TC responded well to treatment with lipid 
lowering agents [47]. Furthermore, in patients with RA, TCZ is able to reduce the levels 
of lipoprotein(a), a molecule closely associated with increased cardiovascular risk [75]. 
Regarding immunogenicity, a total of 2876 patients have been tested for anti-TCZ 
antibodies in the 6-month controlled clinical trials with IV TCZ in patients with RA. Of 
the 46 patients (1.6%) who developed anti-TCZ antibodies, 6 had an associated 
medically significant hypersensitivity reaction, of which 5 led to permanent 
discontinuation of treatment. Only thirty patients (1.1%) developed neutralizing 
antibodies [47]. 
A higher frequency of injection site reactions (ISRs) was observed in patients treated 
with TCZ subcutaneously when compared with those treated IV. The frequency of ISRs 
was 10.1% and 2.4% for the subcutaneous TCZ and the subcutaneous placebo (IV 
group) weekly injections, respectively. These ISRs (including erythema, pruritus, pain 
and hematoma) were mild to moderate in severity. The majority resolved without 
requiring drug discontinuation [47]. 
Overall, the safety profile of TCZ in AOSD seems to be similar to that reported in RA 
patients and other autoimmune diseases. However, while receiving TCZ, some patients 
with AOSD developed MAS [76,77].  
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TCZ should be given in refractory AOSD, because it induces remission allowing 
reduction in the glucocorticoid dose [41,43,50,51,69,78]. Nevertheless, it is important to 
keep in mind that anti-IL-6 agents directly suppress APR production, even in the 
presence of a serious infections leading to septic condition [60]. In addition, TCZ can 
mask the clinical and laboratory features of MAS, and that TCZ itself may also cause 
MAS when it is administered after insufficient additional immunosuppressive therapy 
[79]. In this line, we must be alert to any symptom or sign of MAS in these patients, 
such as high non-remitting fever, central nervous system dysfunction, pancytopenia, 
abnormal coagulation tests, abnormally increased triglycerides or hyperferritinemia 
(generally >5000 mg/L) especially at the beginning of treatment, to avoid the 
development of more serious and irreversible complications. In fact, adequate 
immunosuppression followed by combination of TCZ could be safer than the initial 
administration of TCZ alone in these patients [73,79,80].  
Therefore, it is important to remark that the beneficial role of TCZ in MAS has shown 
conflicting results [81-83]. However, TCZ seems to be truly effective in CRS after 
CART-therapy, a syndrome close resembling MAS [84,85]. 
4.5.6 Special warnings and precautions for use 
Since TCZ generally increases the risk of infections, treatment with TCZ should not be 
initiated in patients with active infections. TCZ administration should be discontinued if 
a patient develops a serious infection until the infection is controlled. Healthcare 
professionals should exercise caution when considering the use of TCZ in patients with 
a history of recurring or chronic infections or with underlying conditions (e.g. 
diverticulitis, diabetes and interstitial lung disease) which may predispose patients to 
infections. Furthermore, the effects of TCZ on CRP, neutrophils and signs of infection 
should be kept in mind when evaluating a patient for a potential infection as signs and 
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symptoms of acute inflammation may be lessened, associated with suppression of the 
acute phase reaction [47]. 
As recommended for other biological therapies, patients should be screened for latent 
tuberculosis (TB) infection prior to starting TCZ. Moreover, patients should be 
instructed to seek medical advice if signs/symptoms (e.g., persistent cough, wasting 
/weight loss, low grade fever) suggestive of a TB infection occur during or after TCZ 
treatment. 
TCZ should be used with caution in patients with previous history of intestinal 
ulceration or diverticulitis because diverticular perforation has been reported in RA 
patients undergoing TCZ therapy as a complication of diverticulitis,   
Caution should be exercised when considering initiation of TCZ treatment in patients 
with elevated ALT or aspartate aminotransferase (AST) > 1.5 times over the upper limit 
of normality (ULN). In patients with baseline ALT or AST > 5 x ULN, treatment with 
TCZ is not recommended. As well, caution should be exercised when considering 
initiation of TCZ in patients with a platelet count < 100 x 103/μL. TCZ should be 
discontinued in patients who develop an absolute neutrophil count (ANC) < 0.5 x 109/L 
or a platelet count < 50 x 103/μ [47]. Nevertheless, although severe neutropenia may be 
associated with an increased risk of serious infections, there was no clear association 
between decreases in neutrophils and the occurrence of serious infections in clinical 
trials with TCZ to date. Table 6 shows some general recommendations that we must 
follow in case of detecting laboratory alterations. 
There are no adequate data from the use of TCZ in pregnant women. A study in animals 
has shown an increased risk of spontaneous abortion/embryo-fetal death at a high dose. 
Thus, TCZ should not be recommended during pregnancy unless clearly necessary. 
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Furthermore, women of childbearing potential must use effective contraception during 
and up to 3 months after treatment [47].   
Finally, live and live attenuated vaccines should not be given concurrently with TCZ as 
clinical safety has not been established. 
4.5.7 Regulatory affairs 
Currently, TCZ is only approved for the treatment of RA, sJIA, pJIA, GCA and 
chimeric antigen receptor (CAR) T cell-induced severe or life-threatening cytokine 
release syndrome (CRS) in adults and pediatric patients 2 years of age and older (Table 
1). However, its indication is not approved for AOSD yet, so its use in this entity must 
be done as off-label medication with prior information to the patient and signature of an 
informed consent previously to start the treatment. 
4.5.8 Conclusions 
Overall, and despite not being approved yet by the regulatory authorities, based on the  
data shown in the different studies mentioned in this review, we conclude that TCZ is 
an effective drug for the overall management of AOSD, both for systemic and joint 
manifestations, as well as for some severe complications of the disease. 
 
5. Expert opinion 
AOSD is a rare multisystem inflammatory disease of unknown origin that is included 
within the clinical spectrum of autoinflammatory disorders [6,7]. Two main clinical 
phenotypes have been recognized in AOSD: a systemic pattern and a CAD [10,19,86-
88]. The systemic pattern may yield more severe and life-threatening complications in a 
short-term but the CAD is more devastating and disabling in the long-term [20]. 
Approximately 60-70% of patients may develop a chronic polyphasic form or CAD. 
MAS is the most important complication of the disease and it may present as the first 
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symptom or during the follow-up period associated with infections, drugs, and disease 
flare ups. Other life-threatening manifestations include disseminated intravascular 
coagulation, pulmonary hypertension, diffuse alveolar hemorrhage, liver failure, 
myocarditis and non-infective thrombotic endocarditis [20,29,89]. 
Since AOSD is an uncommon disease its treatment is not based on controlled clinical 
trials but rather on case reports, case series, non-controlled prospective or retrospective 
studies and extrapolation from experiences in patients with sJIA and auto-inflammatory 
diseases [45,46,90-92]. Conventional treatment consists of NSAIDs, GC, and 
conventional DMARDs. Among them, GC are the keystone of treatment leading to 
remission in around 60% of patients, while the most common DMARDs are MTX and 
cyclosporine. Recent progress in our knowledge of the immunopathogenesis of AOSD 
has enabled us to introduce some specific biologic DMARDs for the treatment of 
AOSD. In this line, the use of anti-TNF, anti-IL-1, and anti-IL-6 agents represents a 
major therapeutic advance in patients with AOSD refractory to conventional therapy 
(Figure 1). 
IL-1 inhibitors may be more efficient for systemic manifestations and IL-6 inhibitor for 
both joint involvement and systemic manifestations, while anti-TNF agents must be 
reserved for patients with typical CAD. An initial application of biological therapy is 
not recommended because around one-third of AOSD patients have a self-limited 
monocyclic pattern. In addition, inadequate use of biologics in the absence of general 
immune suppression may enhance the development of severe life-threatening 
complications such as MAS, so it is recommended to maintain a DMARD associated 
with the biologic to these patients whenever possible.  
It is very important to measure disease activity accurately during the long-term follow-
up of AOSD patients. However, currently available biomarkers have limited value for 
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the therapy and the detection of manifestations of disease. Thus, the development of 
composite biomarkers to detect disease activity including APR, serum ferritin and its 
glycosylated fraction, procalcitonin, calprotectin and serum levels of several ILs (IL-6 
and IL-18) could improve our rational decision-making in the treatment of AOSD [29].  
Among the different biologics available today, TCZ is an effective drug for the global 
treatment of AOSD, both for systemic and articular manifestations, as well as for some 
severe complications of the disease. In this line, TCZ would be indicated in the second 
line after anti-IL-1 agents for systemic manifestations of the disease [3,29,93]. 
Similarly, TCZ could be positioned in the second line of biologic treatment for CAD, 
especially since the appearance of biosimilars of anti-TNFs, given that anti-TNF agents 
are effective in around 30-40% of these patients, which will make these drugs more 
cost-effective, reserving TCZ for a later line of therapy after GC, DMARDs and anti-
TNFα biosimilars failure.  
In order to identify all the available data concerning the effectiveness of biologic drugs 
in AOSD, a systematic review of the literature has been recently performed including 
nineteen observational studies, six of them using TCZ. The pooled analysis under a 
random-effects model showed an overall rate of satisfactory clinical response of 0.85 
(p<0.0001) and an overall rate of complete remission of 0.66 (p=0.01), although the 
heterogeneity across studies was high (Q=59.8 with df=19.0, I2: 68.2%) [94]. 
Taken together, the main limitation to the use of TCZ in AOSD is that this biologic 
agent has not already been approved for this indication. Therefore, its use should be off 
label after failure to GCs, DMARDs and IL-1 or TNF antagonists according to the 
clinical phenotype. In addition, there are some concerns on TCZ use in patients with 
MAS.  
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In a near future, new biological agents against IL-18 or small molecules against Jak-
1/Jak-2 may provide additional therapeutic options for AOSD. Other biologic agents 
that in inhibit IL-6 are currently under investigation. Among them, sirukumab, a human 
monoclonal antibody against IL-6, and sarilumab, an antagonist of IL-6R, are those that 
are in a more advanced phase of development, especially in patients with RA. Both 
molecules are administered subcutaneously every 2-4 weeks and have greater affinity 
for IL-6 than showed by TCZ. However, none of them have proved efficacy in AOSD. 
Furthermore, since levels of sIL-6 increase significantly higher fold compared to 
baseline in active disease, but the fold increase of sIL-6R is much lower than sIL-6, a 
biologic agent blocking sIL-6R such as TCZ would require rather smaller amount of 
antibody to achieve our goal than others blocking sIL-6. 
Figure 1 shows a general therapeutic strategy for patients with active AOSD. 
 
6. Five-year view 
In the following years, a better definition of the AOSD phenotypes will be achieved. 
This fact will allow the clinicians to better identity those patients who would benefit of 
specific biologic agents. New biomarkers on molecules that seem to play a role in the 
pathogenesis of AOSD will help us to better monitor the disease allowing the clinicians 
to improve the evaluation of the risk of relapses [29,95,96]. The development of 
composite outcome measures will be very useful for establishing a rational therapeutic 
strategy in the treatment of patients with AOSD. 
Further treatment options including sarilumab, a new anti-IL-6- agent with greater 
affinity for the IL-6 R than TCZ, inhibitors of intracellular signaling against Jak-1/Jak-2 
and antagonists of IL-18 and IFN-γ need to be tested in patients with refractory AOSD. 
In this line, an open-label, multicentre, dose-escalating phase II clinical trial on the 
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safety and efficacy of tadekinig alpha, a recombinant human IL-18-binding protein (IL-
18BP), in AOSD has been recently published with promising results, although the 
number of patients included was low [97,98].  
 
7. Article Highlights 
• AOSD is a heterogeneous disorder at the crossroads between autoinflammatory and 
autoimmune diseases. 
• Glucocorticoids constitute the first line of treatment for AOSD.  
• Conventional DMARDs, especially MTX, are often considered in refractory cases or as 
GC-sparing agents.  
• Biologic agents must be considered in the management of AOSD refractory to GC and 
conventional DMARDs, since the ultimate goal in the management of AOSD is to 
achieve sustained remission and reduce the risk of relapses and life-threatening 
complications.  
• The development of composite indices based on multiple biomarkers to detect disease 
activity definitely could support rational decision making in the treatment of AOSD. 
• TCZ, a humanized anti-IL-6 receptor antagonist, is an effective drug for the global 
treatment of AOSD, both for systemic and joint manifestations, as well as for some 
severe life-threatening manifestations of the disease. 
• Overall, the benefit/risk ratio and safety profile of TCZ is favorable and similar to that 
described in RA and other rheumatic diseases. However, some cases of MAS have been 
described after the start of treatment with TCZ as well as with other biological agents.  
• Besides the currently available therapeutic options, new biologic agents against IL-18 or 
small molecules against Jak-1/Jak-2 may be additional therapeutic options in AOSD. 
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Drug summary box 
AOSD: adult-onset Still´s disease; IL: interleukin; JIA: juvenile idiopathic arthritis; R: 
receptor; TCZ: tocilizumab. 
 
1 TCZ alone or in combination with methotrexate is indicated for the treatment of 
severe, active and progressive RA in adults not previously treated with methotrexate or 
in patients intolerant or not responders to previous therapy with one or more 
conventional disease-modifying anti-rheumatic drugs or tumor necrosis factor-α 
antagonists. 
2 In patients 2 years of age and older who have responded inadequately to previous 
therapy with non-steroidal anti-inflammatory drugs and systemic glucocorticoids. 
3 Finally, subcutaneous TCZ is recently approved for the treatment of giant cell arteritis 
and intravenous TCZ for the treatment of chimeric antigen receptor (CAR) T cell-
induced severe or life-threatening cytokine release syndrome in adults and pediatric 
patients 2 years of age and older. 
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FIGURE LEGENDS 
Figure 1. Schematic view of the authors for a stepped treatment of AOSD.  
Abbreviations: DMARDs: disease-modifying anti-rheumatic drugs; GC: 
glucocorticoids; Igs: immunoglobulins; inh: inhibitors; IL: interleukin; INF-g: 
interferon-gamma; JAK/STAT: Janus kinase/signal transducers and activators of 
transcription; NSAIDs: non-steroidal anti-inflammatory drugs; OP: osteoporosis; TNF-
α: tumor necrosis factor alfa. 
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Table 1. Useful classification criteria for the diagnosis of adult-onset Still´s disease proposed by Yamaguchi [39] and Fautrel [40]. 
 
      
 
 
 
Abbreviations: AOSD: adult-onset Still´s disease; ANA: antinuclear antibodies; RF: rheumatoid factor. 
Yamaguchi´s classification criteria for diagnosis of AOSD (1992) 
 
Major criteria: 
1. Fever ≥ 39ºC lasting ≥ 1 week 
2. Arthralgia or arthritis  lasting ≥ 2 weeks 
3. Typical nonpruritic salmon-pink skin rash 
4. Leukocytosis ≥ 10,000/mm3 with  granulocytes ≥ 80%  
 
Minor criteria: 
1. Sore throat 
2. Lymph node enlargement 
3. Hepatomegaly or splenomegaly  
4. Abnormal liver function tests 
5. Negative ANA and RF tests 
 
Exclusion criteria: 
1. Infections 
2. Malignancy (mainly malignant lymphoma) 
3. Other systemic disorders (mainly vasculitis) 
(≥ 5 criteria are required with at least 2 being major criteria  
AND no exclusion criteria) 
Fautrel´s classification criteria for diagnosis of AOSD (2002) 
 
Major criteria: 
1. Spiking fever ≥ 39ºC 
2. Arthralgias 
3. Transient erythema 
4. Pharyngitis 
5. Polymorphonuclear cells ≥ 80% 
6. Glycosylated ferritin ≤ 20% 
 
Minor criteria: 
1. Maculopapular rash 
2. Leukocytosis > 10,000/mm3 
(≥ 4 major criteria or 3 major + 2 minors are required) 
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Table 2. Main indications approved and off-label for the use of tocilizumab today. 
 
 
 
 
 
 
 
 
Abbreviations: CAR: chimeric antigen receptor; TCZ: tocilizumab. 
*In all described scenarios, especially for patients refractory to conventional therapies. 
 
 
 
 
Indications approved and off label for the use of TCZ*
Approved: 
 
- Rheumatoid arthritis 
- Systemic juvenile idiopathic arthritis (sJIA) 
- Polyarticular juvenile idiopathic arthritis (pJIA) 
- CAR T cell-induced cytokine release syndrome (CRS) 
- Giant cell arteritis (only subcutaneous administration) 
 
Off-label: 
 
- Adult-onset Still´s disease (AOSD) 
- Autoinflammatory syndromes 
- Other inflammatory arthropaties 
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Table 3. Efficacy of tocilizumab in AOSD: summary of data of the first clinical trial with tocilizumab and main prospective and retrospective 
studies published up to date#. 
Author 
(Country) 
[Ref. number]  
Number  
of patients  
(Sex)  
Previous 
treatment  
(n) 
Dose (n) 
Duration of treatment 
Overall response  
% (n)  
Glucocorticoid 
before and 
after treatment 
(mg/day)* 
 Reasons for withdrawal 
(n) 
Ortiz-Sanjuán 
(Spain) [50] 
34 
(26W, 8M) 
MTX (31), LEF 
(5), CsA (2), 
a-TNF (18) 
RTX (6), ABT (2) 
8 mg/kg/2 wks (10) 
8 mg/kg/4 wks (22) 
4 mg/kg/4 wks (2) 
TCZ monother (15) 
12 months duration 
Arthritis from 97.1% to 
32.4%; skin rash and 
fever from 58.8% to  
5.9% equally  
13.8; 2.5 §  Infection, severe (2): 
pyelonephritis (1), bacterial 
spondylodiscitis (1) 
Kaneko et al.  
(Japan) [54] 
27 
(20W, 7M) 
NS; use of 
concomitant 
DMARDs or IS 
was prohibited 
during the study 
8 mg/kg vs. 
placebo during 
12 wks; open-label 
TCZ for 40 weeks 
subsequently 
Systemic feature score 
was -4.1 in the TCZ group 
and -2.3 in the placebo 
group (p=0.003) at week 
12th 
Decreased by 
46.2% in TCZ 
and 21.0% in 
the pbo group 
after 12 weeks 
 Anaphylactic shock to TCZ 
in 1 patient. Infusion 
reactions occurred in 5, of 
whom 4 received TCZ and 
1 placebo. AEs led to TCZ 
cessation in 2 patients 
Song et al. 
(Korea) [51] 
 
 
22  
(NS) 
 
 
MTX (20), LEF 
(12), AZA (9), 
CsA (8), a-TNF 
(18), ANK (1), 
ABT (2) 
8 mg/kg/4 wks (18) 
6 mg/kg/4 wks (2)  
4 mg/kg/4 wks (2) 
7.5 months duration  
Good response: 50%            
at 6 m; 64.3% at 12 m. 
Partial response: 31.8%  
at 6 months; 14.3% at 12 
months 
 11.5 before; 
 7.5 after 6 m; 
 6.3 after 12 m
 
 Hypertension and face 
swelling (1) 
Elkayam et al. 
(Israel) [43]  
 
 
 
15 
(9M, 6W) 
 
 
 
DMARDs (15) 
Anti-TNF (10) 
 
 
 
8 mg/kg/2 wks (3) 
8 mg/kg/4 wks (12) 
6 months duration 
 
 
Responders 86.7% 
(13/15) 
 
 
 
 27.6; 3.8 
 
 
 
 
 MAS (1) 
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Abbreviations in alphabetic order: ABT: abatacept; AEs: adverse events; ANK: anakinra; anti(a)-TNF: anti-tumor necrosis factor; AOSD: adult-onset Still´s 
disease; AZA: azathioprine; bio: biologic therapy; CsA: cyclosporin A; (b)DMARDs: (biological) disease-modifying antirheumatic drug; EULAR: European 
League against Rheumatism; IS: immunosuppressive agents; LEF: leflunomide; M: male: m (mo): months; MAS: macrophage activation syndrome; MTX: 
methotrexate; monother: monotherapy; n: number; NS: non specified; pbo: placebo; RTX: rituximab; TCZ: tocilizumab; UTI: urinary tract infection; W: 
women; wks: weeks. 
*Values are expressed as mean, unless otherwise expressed; § Values in these 2 series are expressed as median. 
¶ In no case it forced the suspension of the drug. 
# Based on data of ref. [32] 
Puéchal et al.    
(France) [30]  
 
14 
(9W, 5M) 
 
  
MTX (14), ANK 
(14), a-TNF (12), 
ABT/RTX (7) 
8 mg/kg/2 wks (4) 
8 mg/kg/4 wks (9) 
5 mg/kg/4 wks (1) 
6 months duration 
EULAR remission 54% 
(8/14). Systemic symptom 
resolved in 86% (7/8)  
at 6 months 
 
 23.3; 10.3 Necrotizing 
angiodermatitis (1) 
Chest pain (1) 
Systemic flare (1) 
  
Suematsu et al. 
(Japan) [52] 
 
11 
(9W, 2M) 
TCZ first bio line 
in 6; switching 
from another bio 
in 5 
8 mg/kg/4 wks (11) 
11.6 months duration      
Remission in 10/11 Decrease in 
GC dose of 
16.8 mg/day 
 Stomatitis (1), UTI (1), 
liver dysfunction (1) ¶ 
Cipriani et al.         11                   MTX (8)                   8 mg/kg/4 wks (11)          EULAR remission 81.8%      50; 0 at 12 mo §        Non reported 
(Italy) [41]             (6W, 5M)                                         12 months duration          (9/11) at 12 months                8/11 discontinued                                                   
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Table 4. Efficacy of tocilizumab in adult-onset Still´s disease: additional studies with n ≤ 10 cases per study. 
Author 
(Country) 
[Ref. number]  
Number  
of patients  
(Sex)  
Previous 
treatment  
(n) 
Dose (n) 
Duration of treatment 
Overall response  
% (n)  
Glucocorticoid 
before and 
after treatment 
(mg/day)* 
 Safety of the drug and AEs 
(n) 
Nishina et al.  
(Japan) [31]  
 
 
 
 
Takakuwa et al. 
(Japan) [53] 
10 
(6W, 4M) 
 
 
 
 
9  
(8W, 1M) 
  
MTX (6),  
TCR (2),  
CsA (1) 
 
 
 
 
DMARDs (NS) 
anti-TNF (7) 
8 mg/kg/2 wks (6) 
8 mg/kg/4 wks (4) 
6-12 months duration 
 
 
 
 
Non specified 
 
 
  
No relapses during TCZ 
therapy vs 11 before therapy; 
4 pts discontinued therapy 
due to sustained remission; 
although 2/4 pts relapsed 6 
and 14 mo later withdrawal 
 
 
TCZ induced higher clinical 
remission than a-TNF agents 
(5/7 vs 2/10, p=0.05); 
4/5 pts who switched from a-
TNF to TCZ achieved 
clinical remission 
  20; 11§ 
 
 
 
 
  
 
 Non reported 
 
 
 
 
 4 pts were hospitalized a total 
of 9 times due to infection  
(1 case), orthopedic surgery  
(4 cases in 2 pts), malignancy  
(2 cases in 1 pt) and others (2 
cases in 2 pts). No 
discontinuation due to AEs 
 
During treatment with a-TNF, 
severe AEs were observed in 
4 pts, which included ovarian 
cancer, severe hepatitis, CMV 
infection, and infusion 
reaction; no AEs were 
observed during TCZ therapy 
 
Li et al.                  8                   DMARDs (7),         4-8 mg/kg/4 weeks (8)    Complete remission                    51.7; 12.9                  Infusion reactions (2), 
(China) [57]          (8W)             bDMARDs (NS)     ≥ 3 months follow-up      87.5% (7/8) at 3 months                                               infections (3, two with UTI),     
                                                                                                                                                                                                                  MAS (1) ¶
 
Bannai et al.          7                   MTX (3), CsA (2)    8 mg/kg/2 wks (6)          Good response in all (7)            Decrease in GC         AEs occurred in 3 pts: 
(Japan) [60]           (4W, 3M)     IFX (1), ETA (1),     8 mg/kg/4 wks (1)          without any flares                     dose of 26.1 mg/d      MAS, CMV (2 episodes) 
                                                   TCR (1), BUC (1)                                                                                              1/7 discontinued        and clostr. difficile in 1 pt,  
                                                                                                                                                                                                                 CMV and MAS in other pt ¥;  
                                                                                                                                                                                                                 Suicide (1) ¶¶ 
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pt Abbreviations in alphabetic order: ABT: abatacept; AEs: adverse events; ANK: anakinra; anti(a)-TNF: anti-tumor necrosis factor; AZA: azathioprine; BUC: bucillamine; clostr.: clostridium; CMV: cytomegalovirus infection; CsA: cyclosporin A; (b)DMARDs: (biological) disease-modifying antirheumatic drug; 
ETA: etanercept; EULAR: European League against Rheumatism; GC: glucocorticoids; IFX: infliximab; LEF: leflunomide; M: male: MAS: macrophage 
activation syndrome; MTX: methotrexate; mo: months; n: number; NS: non specified; pt(s): patient(s); RTX: rituximab; TCR: tacrolimus; TCZ: tocilizumab; 
UTI: urinary tract infection; VZV: varicella-zoster virus reactivation; W: women; wks: weeks.  
¥The MAS was treated and resolved in both patients.  
¶ In no case it forced the suspension of the drug.  
¶¶ A case of suicide due to schizophrenia despite that AOSD was stabilized after introducing TCZ. 
Cavalli et al.         4                    MTX (3), CsA (1),    Non reported                 Complete response (2),             Decrease in GC,         HVZ (1) 
(Italy) [61]           (3W, 1M)      ANK (3), ETA (2)                                            Partial response (1),                  1/4 discontinued 
                                                                                                                            Failure (1)                                                                                                               
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Table 5. Main adverse effects of TCZ according to the MedDRA Organ System 
Classification#.  
 
 
Abbreviations: MedDRA: Medical Dictionary for Regulatory Activities. 
Adverse reactions are listed according to MedDRA system organ class and frequency.  
*Frequency categories are defined using the following criteria: very common (≥ 1/10); common 
(≥ 1/100 to < 1/10); uncommon (≥ 1/1,000 to < 1/100); rare (≥ 1/10,000 to < 1/1,000); very rare 
(< 1/10,000). ISR: Injection site reactions; TCZ: tocilizumab. 
MedDRA  
Organ System  
Classification 
Frequency categories with preferred terms* 
 
Very common                       Common                         Uncommon 
Infections and 
infestations 
Upper respiratory            Cellulitis, pneumonia,          Diverticulitis 
tract infections                 oral herpes simplex, 
                                         herpes zoster 
Skin and subcutaneous 
tissue disorders  
 Rash, pruritus,  
urticaria 
 
Gastrointestinal  
complications 
 
Nervous system                 
manifestations  
 Abdominal pain, mouth 
ulcers, gastritis, diarrhea 
 
Headache, dizziness 
 
 Stomatitis,      
 gastric ulcer 
 
Laboratory  
abnormalities        
 
 Hepatic transaminases  
increased, total bilirubin  
increased¶ 
 
 
Blood and lymphatic         
disorders                            
 
                                         Leukopenia, neutropenia 
 
 
Metabolism and 
nutrition disorders  
Hypercholes- 
terolemia¶ 
Weight increased, 
hypertension 
Hypertriglyceri-
demia 
General disorders  
and administration  
site reactions 
Injection site  
reactions (ISR)§ 
Peripheral edema, 
hypersensitivity  
reactions 
 
Respiratory, thoracic & 
mediastinal 
manifestations  
 
Renal diseases                   
 
Endocrine disorders 
 
Eye disorders 
 
 
 
 
 
 
 
 
 
 
Cough, dyspnea 
 
 
 
 
 
                                        
 
Conjunctivitis 
 
 
 
 
Nephrolithiasis 
 
Hypothyroidism 
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¶ Includes elevations disclosed as part of the routine laboratory monitoring. 
§ Mainly following subcutaneous administration.  
Most results shown in the table are obtained from double-blind controlled studies performed in 
patients with rheumatoid arthritis receiving tocilizumab as monotherapy or in combination with 
disease-modifying anti-rheumatic drugs (DMARDs). 
# Modified from ref. [47]. 
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Table 6. Management of main laboratory abnormalities detected in adults with RA receiving treatment with TCZ in monotherapy or in 
combination with disease-modifying anti-rheumatic drugs (DMARDs)#. 
Laboratory abnormalities TCZ intravenous 
“ACTION TO TAKE” 
TCZ subcutaneous 
“ACTION TO TAKE” 
Absolute neutrophil count (ANC)* (cells x 109/L) 
ANC > 1  
 
Maintain dose  Maintain dose 
ANC ≥ 0.5 and ≤ 1  Interrupt TCZ dosing 
 
When ANC increases > 1 x 109/L restart  
TCZ at 4 mg/kg and increase to 8 mg/kg,  
as clinically appropriate  
 
Interrupt TCZ dosing 
 
When ANC increases > 1 x 109/L restart TCZ 
dosing every other week and increase to every 
week injection, as clinically appropriate 
ANC < 0.5  Discontinue TCZ  Discontinue TCZ 
Low platelet count (cells x 103/µL) 
50 to 100 Interrupt TCZ dosing 
 
When platelet count > 100 x 103/μL restart   
TCZ at 4 mg/kg and increase to 8 mg/kg  
as clinically appropriate  
 
Interrupt TCZ dosing 
 
When platelet count > 100 x 103/μL restart TCZ 
dosing every other week and increase to every 
week injection, as clinically appropriate 
< 50  
 
Discontinue TCZ  
 
Discontinue TCZ  
 
Liver enzyme abnormalities 
> 1 to 3 x Upper Limit of Normal (ULN)  
 
Modify the dose of the concomitant MTX  
if appropriate  
 
Modify dose of MTX or DMARDs, or of the 
immunomodulatory agents (in case of GCA), 
if appropriate 
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For persistent increases in this range, reduce TCZ 
dose to 4 mg/kg or interrupt TCZ until ALT or 
AST have normalized 
 
Restart with 4 mg/kg or 8 mg/kg, as clinically 
appropriate  
 
For persistent increases in this range, reduce TCZ 
dose frequency to every other week injection or 
interrupt TCZ until ALT or AST have normalized 
 
Restart with weekly or every other week injection, 
as clinically appropriate 
 
> 3 to 5 x ULN  
(confirmed by repeating testing)  
Interrupt TCZ dosing until < 3 x ULN and follow 
recommendations above for > 1 to 3 x ULN.  
 
For persistent increases > 3 x ULN, discontinue 
TCZ 
 
Interrupt TCZ dosing until < 3 x ULN and follow 
recommendations above for > 1 to 3 x ULN 
 
For persistent increases > 3 x ULN (confirmed by 
repeat testing), discontinue TCZ 
 
> 5 x ULN  
 
Discontinue TCZ  
 
Discontinue TCZ  
 
Abbreviations: ALT: alanine aminotransferase; ANC: absolute neutrophil count; AOSD: adult-onset Still´s disease; AST: aspartate aminotransferase; 
DMARDs: disease-modifying anti-rheumatic drugs; GCA: giant cell arteritis; MTX: methotrexate; RA: rheumatoid arthritis; TCZ: tocilizumab; ULN: upper 
limit of normality. * In patients not previously treated with TCZ, initiation is not recommended in patients with an ANC < 2 x 109/L.  
Data of toxicity in laboratory parameters in patients with AOSD are less studied. 
# Modified from ref. [47]  
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